Peter Tontonoz, M.D., Ph.D., Frances and Albert Piansky Professor of Pathology and Laboratory Medicine at the David Geffen School of Medicine of UCLA will present the 2017-2018 Harry E. Bovay, Jr. Annual Lecture on “Nuclear Receptors and Lipid Metabolism.”
The lecture will be held at 11AM Dec. 15 in SRB 104 (Beth Robertson Auditorium at IMM, 1825 Pressler St.).
Tontonoz is the Frances and Albert Piansky Professor of Pathology and Laboratory Medicine and David Geffen School of Medicine Dean’s Scholar at the University of California, Los Angeles. Tontonoz received his B.A. from Wesleyan University and his M.D. and Ph.D. from Harvard Medical School. The focus of his laboratory is the control of gene expression by lipids and the role of nuclear receptors in lipid metabolism. Tontonoz’s work has helped to elucidate fundamental mechanisms by which animals maintain cellular and whole-body lipid homeostasis. He has revealed new pathways for regulation of cholesterol uptake and efflux from cells, and has shown how these pathways impact the function of immune cells in both physiology and disease. Major research contributions include the delineation of role of lipid-activated transcription factors in adipogenesis and atherosclerosis, and elucidation of mechanisms of crosstalk between metabolism, inflammation and immunity.
Tontonoz is a recipient of the Richard Weitzman Award and the Gerald D. Aurbach Award from the Endocrine Society, and the Jeffrey Hoeg Award for Basic Science and Clinical Research from the American Heart Association. He is a past President of the American Society for Clinical Investigation. Tontonoz serves on a number of editorial boards and is the Editor in Chief of Molecular and Cellular Biology.
This lecture series honors the life and work of Harry E. Bovay, Jr., 1914-2011, distinguished visionary, entrepreneur, civic leader, and philanthropist, who made a significant contribution to the Brown Foundation of Institute of Molecular Medicine for the Prevention of Human Diseases (IMM) to help bridge the gap between the laboratory bench and the patient bedside, between identifying the molecular causes of diseases and actually preventing them.